Contributions
Abstract: EP1666
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Introduction: Teriflunamide (TRF) and dimethyl fumarate (DMF) are first-line oral immunomodulators approved for replasing-remitting multiple sclerosis (MS) treatment. They have comparable efficacy with injectable drugs and are more convenient for patients.
Aim: To compare demographic and clinical characteristics between MS patients under TRF and DMF and to compare tolerability and efficacy.
Results: Clinical data from 30 MS patients under TRF and 50 MS patients under DMF was reviewed. All had relapsing-remitting type except for 2 patients under TRF who had secondary progressive type. MS patients under TRF were older (46.9 ± 10.3 vs 36,5 ± 9.4, p< 0.001) with no difference in gender (p=0.49). MS patients under TRF presented superior baseline EDSS (4 vs 1, p< 0.001) but no difference in relapse rate for the last 12 months was found (0.5 vs 1, p=0.98). The mean follow-up time was 14.5±10.7 months for DMF group and 8.3±5.7 months for TRF group. DMF and TRF were equally chosen for naïve patients. Treatment was changed to TRF or DMF due to adverse events in 55% and due to therapy failure in 26%. DMF had to be stopped in 7 patients (14%) due to intolerance (gastrointestinal symptoms, recurrent infections and lymphopenia) and in 3 patients (6%) due to clinical failure. TRF was stopped in 4 patients (13%) due to intolerance (toxic hepatitis, pancytopenia, epilepsy and recurrent infection) and in 1 patient (3%) due to severe alopecia and failure to prevent relapse. In those with more than 6 months of follow-up, the average relapse rate (p=0.77) and EDSS progression (p=0.29) were not different between groups.
Conclusion: TRF was the drug of choice for older and more disabled patients. Tolerability and efficacy were similar for both drugs.
Disclosure: Nothing to declare.
Abstract: EP1666
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Introduction: Teriflunamide (TRF) and dimethyl fumarate (DMF) are first-line oral immunomodulators approved for replasing-remitting multiple sclerosis (MS) treatment. They have comparable efficacy with injectable drugs and are more convenient for patients.
Aim: To compare demographic and clinical characteristics between MS patients under TRF and DMF and to compare tolerability and efficacy.
Results: Clinical data from 30 MS patients under TRF and 50 MS patients under DMF was reviewed. All had relapsing-remitting type except for 2 patients under TRF who had secondary progressive type. MS patients under TRF were older (46.9 ± 10.3 vs 36,5 ± 9.4, p< 0.001) with no difference in gender (p=0.49). MS patients under TRF presented superior baseline EDSS (4 vs 1, p< 0.001) but no difference in relapse rate for the last 12 months was found (0.5 vs 1, p=0.98). The mean follow-up time was 14.5±10.7 months for DMF group and 8.3±5.7 months for TRF group. DMF and TRF were equally chosen for naïve patients. Treatment was changed to TRF or DMF due to adverse events in 55% and due to therapy failure in 26%. DMF had to be stopped in 7 patients (14%) due to intolerance (gastrointestinal symptoms, recurrent infections and lymphopenia) and in 3 patients (6%) due to clinical failure. TRF was stopped in 4 patients (13%) due to intolerance (toxic hepatitis, pancytopenia, epilepsy and recurrent infection) and in 1 patient (3%) due to severe alopecia and failure to prevent relapse. In those with more than 6 months of follow-up, the average relapse rate (p=0.77) and EDSS progression (p=0.29) were not different between groups.
Conclusion: TRF was the drug of choice for older and more disabled patients. Tolerability and efficacy were similar for both drugs.
Disclosure: Nothing to declare.